Eichhorn, Florian
Klotz, Laura V.
Bischoff, Helge
Thomas, Michael
Lasitschka, Felix
Winter, Hauke
Hoffmann, Hans
Eichhorn, Martin E.
Funding for this research was provided by:
Oncology Merck Investigator Studies Program (MISP), MSD SHARP & DOHME GMBH, Germany (MISP 52887)
Article History
Received: 23 July 2018
Accepted: 18 April 2019
First Online: 2 May 2019
Ethics approval and consent to participate
: The authors declare that they have followed the ethical standards of the responsible committees on human experimentation:1. Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines, Paul-Ehrlich-Str. 51–59, 63225 Langen, Germany, Phone: + 49 6103 77 0 / Email: ExternalRef removed2. Ethikkommission der Universität Heidelberg, Alte Glockengießerei 11/1; D-69115 Heidelberg, + 49 6221 33822–0 / Email: ExternalRef removed.The regulatory committees have declared that all regulatory requirements are in place to start with the NEOMUN 0316-ASG study. Approvals are available from the corresponding author on reasonable request.Written informed consent for scientific analysis of clinical details and/or associated medical data or study-related results is obtained from the participant before trial inclusion and can be made available on request.
: N/A.
: The authors declare that they have no competing interest.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.